Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations. Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards. With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Alembic Pharmaceuticals's score of 70 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Alembic Pharmaceuticals reported total greenhouse gas emissions of approximately 909,814,000 kg CO2e. This figure includes 86,096,000 kg CO2e from Scope 1 emissions, 67,544,000 kg CO2e from Scope 2, and a significant 756,174,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 532,857,000 kg CO2e. Alembic Pharmaceuticals has set ambitious climate commitments, aiming for a 63% reduction in absolute greenhouse gas emissions across all scopes by FY2034, using FY2022 as the baseline. Furthermore, the company is committed to achieving net-zero emissions by 2050. This long-term goal aligns with their strategy to reduce emissions by 90% from the FY2022 baseline by 2050. The company has demonstrated a proactive approach to sustainability, with a focus on reducing emissions intensity per employee and per unit of production. In 2023, the total Scope 1 and Scope 2 emissions intensity was reported at 25,000 kg CO2e per tonne of output, and 10,000 kg CO2e per employee. Alembic Pharmaceuticals' climate strategy reflects a commitment to addressing climate change and reducing their carbon footprint in the pharmaceutical sector, aligning with global sustainability goals.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | |
---|---|---|---|
Scope 1 | - | 00,000,000 | 00,000,000 |
Scope 2 | - | 00,000,000 | 00,000,000 |
Scope 3 | - | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.